Bausch Health CFO Sizes Xifaxan Medicare Price Change At $400 Million To $500 Million A Year

JJ Charron gave the dollar figure after an analyst asked for it, and said fourth-quarter growth will be trimmed by an inventory accrual.

Share
Bausch Health CFO Sizes Xifaxan Medicare Price Change At $400 Million To $500 Million A Year

Bausch Health Chief Financial Officer JJ Charron said on the company's Wednesday earnings call that the net impact of the new Medicare price on Xifaxan is around $400 million to $500 million year over year. An Evercore ISI analyst had asked him to state in dollars what the company had so far given only in basis points.

Charron's dollar figure

Bausch Health is a specialty drug and device company whose Salix unit sells Xifaxan, a gastrointestinal drug. Charron split the Medicare price change into two parts. The first is a gross-to-net accrual, an accounting adjustment tied to inventory in the sales channel and booked ahead of the new price. He put it at "in excess of $100 million."

The second is the effect of the Medicare rebate under the Inflation Reduction Act. The company has not provided specific details, Charron said, adding that the information is public. He said the starting point is a price increase, followed by a rebate down to a fixed price negotiated in September of 2024.

He said the implicit 2027 guidance, which he put at "about $2.7 billion," lets investors infer that the net of "all the puts and takes" is "around $400 to $500 million of dollars year over year." He called that "a good order of magnitude" for the Medicare effect. The new price takes effect on January 1, 2027.

A fourth-quarter drag

Charron said the channel-inventory accrual alone will cut fourth-quarter revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points. Basis points are hundredths of a percentage point. The company's guidance also assumes some normalization of Xifaxan inventory, which he said could take at least another 300 basis points off revenue growth and 500 off adjusted EBITDA growth.

Third-quarter results were strong. Salix revenue was $831 million, up $115 million, and Xifaxan grew 16%, which Charron attributed to favorable net realized pricing and solid demand. Total retail prescriptions excluding Medicaid rose 1.8%. He cautioned that third-quarter volume growth also got a lift from higher channel inventory.

Guidance raised again

Bausch Health, excluding Bausch + Lomb, reported third-quarter revenue of $1,566 million, up 12%, and adjusted EBITDA of $1,022 million. Charron raised full-year 2026 guidance for the second quarter in a row. Revenue is now expected at $5,525 million to $5,625 million, adjusted EBITDA at $3,225 million to $3,275 million, and adjusted cash flow from operations at $1,600 million to $1,675 million.

The company has $2 billion in cash. Charron said it plans early redemptions of its 2027 notes and up to $100 million of open-market repurchases of its public debt. It also announced a $50 million share buyback, aimed mainly at offsetting dilution from management equity awards expected to vest in 2027.

The next marker is January 1, 2027, when the new Medicare price for Xifaxan starts.

Sources

More on Bausch Health

All Bausch Health (BHC) coverage →